3 Healthcare Stock Stories for Weekend Wellness

Avanir Pharmaceuticals (NASDAQ: AVNR): Closing price $3.29

Avanir announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and quinidine sulfate), recommending that he drug be okayed for the treatment of pseudobulbar affect, regardless of neurologic cause. Beyond that, the CHMP also recommended clearance of two dose strengths of Nuedaxta; 20/10 mg and 30/10 mg capsules.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AVNR

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Closing price $27.28

On Friday, Ligand said that data from preclinical studies evaluating the company’s HepDirect liver-targeting tech platform will be featured in a poster presentation at the 48th Annual International Liver Congress hosted by the European Association for the Study of the Liver inAmsterdam. The data indicate highly targeted liver delivery of a clinically active NS5B polymerase inhibitor, employing the HepDirect technology platform, and demonstrated that HepDirect liver targeting of active nucleosides could be an effective method to enhance efficacy while lowering systemic side effects in HCV treatment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LGND

CareFusion Corp. (NYSE: CFN): Closing price $33.76

CareFusion has announced an agreement in principle to settle previously-reported government investigations in regards to prior sales and marketing practices for its ChloraPrep skin preparation product and its relationships with health care professionals. The firm expects to pay the government roughly $41 million through which to resolve the claims. CareFusion will record the charge in the third quarter of fiscal 2013 to set up a reserve for the amount.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CFN

Investing Insights: Is Vivus Undervalued?

More from The Cheat Sheet